Metformin targets c-MYC oncogene to prevent prostate cancer

Tunde Akinyeke, Satoko Matsumura, Xinying Wang, Yingjie Wu, Eric D. Schalfer, Anjana Saxena, Wenbo Yan, Susan K. Logan, Xin Li

Research output: Contribution to journalArticle

Abstract

Prostate cancer (PCa) is the second leading cause of cancerrelated death in American men and many PCa patients develop skeletal metastasis. Current treatment modalities for metastatic PCa are mostly palliative with poor prognosis. Epidemiological studies indicated that patients receiving the diabetic drug metformin have lower PCa risk and better prognosis, suggesting that metformin may have antineoplastic effects. The mechanism by which metformin acts as chemopreventive agent to impede PCa initiation and progression is unknown. The amplification of c-MYC oncogene plays a key role in early prostate epithelia cell transformation and PCa growth. The purpose of this study is to investigate the effect of metformin on c-myc expression and PCa progression. Our results demonstrated that (i) in Hi-Myc mice that display murine prostate neoplasia and highly resemble the progression of human prostate tumors, metformin attenuated the development of prostate intraepithelial neoplasia (PIN, the precancerous lesion of prostate) and PCa lesions. (ii) Metformin reduced c-myc protein levels in vivo and in vitro. In Myc-CaP mouse PCa cells, metformin decreased c-myc protein levels by at least 50%. (iii) Metformin selectively inhibited the growth of PCa cells by stimulating cell cycle arrest and apoptosis without affecting the growth of normal prostatic epithelial cells (RWPE-1). (iv) Reduced PIN formation by metformin was associated with reduced levels of androgen receptor and proliferation marker Ki-67 in Hi-Myc mouse prostate glands. Our novel findings suggest that by downregulating c-myc, metformin can act as a chemopreventive agent to restrict prostatic neoplasia initiation and transformation.

Original languageEnglish (US)
Pages (from-to)2823-2832
Number of pages10
JournalCarcinogenesis
Volume34
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Metformin
Oncogenes
Prostatic Neoplasms
Prostate
Proto-Oncogene Proteins c-myc
Neoplasms
Growth
Androgen Receptors
Cell Cycle Checkpoints
Antineoplastic Agents
Epidemiologic Studies
Cause of Death
Down-Regulation
Epithelium
Epithelial Cells
Apoptosis
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research

Cite this

Akinyeke, T., Matsumura, S., Wang, X., Wu, Y., Schalfer, E. D., Saxena, A., ... Li, X. (2013). Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis, 34(12), 2823-2832. https://doi.org/10.1093/carcin/bgt307

Metformin targets c-MYC oncogene to prevent prostate cancer. / Akinyeke, Tunde; Matsumura, Satoko; Wang, Xinying; Wu, Yingjie; Schalfer, Eric D.; Saxena, Anjana; Yan, Wenbo; Logan, Susan K.; Li, Xin.

In: Carcinogenesis, Vol. 34, No. 12, 12.2013, p. 2823-2832.

Research output: Contribution to journalArticle

Akinyeke, T, Matsumura, S, Wang, X, Wu, Y, Schalfer, ED, Saxena, A, Yan, W, Logan, SK & Li, X 2013, 'Metformin targets c-MYC oncogene to prevent prostate cancer', Carcinogenesis, vol. 34, no. 12, pp. 2823-2832. https://doi.org/10.1093/carcin/bgt307
Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013 Dec;34(12):2823-2832. https://doi.org/10.1093/carcin/bgt307
Akinyeke, Tunde ; Matsumura, Satoko ; Wang, Xinying ; Wu, Yingjie ; Schalfer, Eric D. ; Saxena, Anjana ; Yan, Wenbo ; Logan, Susan K. ; Li, Xin. / Metformin targets c-MYC oncogene to prevent prostate cancer. In: Carcinogenesis. 2013 ; Vol. 34, No. 12. pp. 2823-2832.
@article{e72e751dc6cc423f83d8bf0b60237172,
title = "Metformin targets c-MYC oncogene to prevent prostate cancer",
abstract = "Prostate cancer (PCa) is the second leading cause of cancerrelated death in American men and many PCa patients develop skeletal metastasis. Current treatment modalities for metastatic PCa are mostly palliative with poor prognosis. Epidemiological studies indicated that patients receiving the diabetic drug metformin have lower PCa risk and better prognosis, suggesting that metformin may have antineoplastic effects. The mechanism by which metformin acts as chemopreventive agent to impede PCa initiation and progression is unknown. The amplification of c-MYC oncogene plays a key role in early prostate epithelia cell transformation and PCa growth. The purpose of this study is to investigate the effect of metformin on c-myc expression and PCa progression. Our results demonstrated that (i) in Hi-Myc mice that display murine prostate neoplasia and highly resemble the progression of human prostate tumors, metformin attenuated the development of prostate intraepithelial neoplasia (PIN, the precancerous lesion of prostate) and PCa lesions. (ii) Metformin reduced c-myc protein levels in vivo and in vitro. In Myc-CaP mouse PCa cells, metformin decreased c-myc protein levels by at least 50{\%}. (iii) Metformin selectively inhibited the growth of PCa cells by stimulating cell cycle arrest and apoptosis without affecting the growth of normal prostatic epithelial cells (RWPE-1). (iv) Reduced PIN formation by metformin was associated with reduced levels of androgen receptor and proliferation marker Ki-67 in Hi-Myc mouse prostate glands. Our novel findings suggest that by downregulating c-myc, metformin can act as a chemopreventive agent to restrict prostatic neoplasia initiation and transformation.",
author = "Tunde Akinyeke and Satoko Matsumura and Xinying Wang and Yingjie Wu and Schalfer, {Eric D.} and Anjana Saxena and Wenbo Yan and Logan, {Susan K.} and Xin Li",
year = "2013",
month = "12",
doi = "10.1093/carcin/bgt307",
language = "English (US)",
volume = "34",
pages = "2823--2832",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Metformin targets c-MYC oncogene to prevent prostate cancer

AU - Akinyeke, Tunde

AU - Matsumura, Satoko

AU - Wang, Xinying

AU - Wu, Yingjie

AU - Schalfer, Eric D.

AU - Saxena, Anjana

AU - Yan, Wenbo

AU - Logan, Susan K.

AU - Li, Xin

PY - 2013/12

Y1 - 2013/12

N2 - Prostate cancer (PCa) is the second leading cause of cancerrelated death in American men and many PCa patients develop skeletal metastasis. Current treatment modalities for metastatic PCa are mostly palliative with poor prognosis. Epidemiological studies indicated that patients receiving the diabetic drug metformin have lower PCa risk and better prognosis, suggesting that metformin may have antineoplastic effects. The mechanism by which metformin acts as chemopreventive agent to impede PCa initiation and progression is unknown. The amplification of c-MYC oncogene plays a key role in early prostate epithelia cell transformation and PCa growth. The purpose of this study is to investigate the effect of metformin on c-myc expression and PCa progression. Our results demonstrated that (i) in Hi-Myc mice that display murine prostate neoplasia and highly resemble the progression of human prostate tumors, metformin attenuated the development of prostate intraepithelial neoplasia (PIN, the precancerous lesion of prostate) and PCa lesions. (ii) Metformin reduced c-myc protein levels in vivo and in vitro. In Myc-CaP mouse PCa cells, metformin decreased c-myc protein levels by at least 50%. (iii) Metformin selectively inhibited the growth of PCa cells by stimulating cell cycle arrest and apoptosis without affecting the growth of normal prostatic epithelial cells (RWPE-1). (iv) Reduced PIN formation by metformin was associated with reduced levels of androgen receptor and proliferation marker Ki-67 in Hi-Myc mouse prostate glands. Our novel findings suggest that by downregulating c-myc, metformin can act as a chemopreventive agent to restrict prostatic neoplasia initiation and transformation.

AB - Prostate cancer (PCa) is the second leading cause of cancerrelated death in American men and many PCa patients develop skeletal metastasis. Current treatment modalities for metastatic PCa are mostly palliative with poor prognosis. Epidemiological studies indicated that patients receiving the diabetic drug metformin have lower PCa risk and better prognosis, suggesting that metformin may have antineoplastic effects. The mechanism by which metformin acts as chemopreventive agent to impede PCa initiation and progression is unknown. The amplification of c-MYC oncogene plays a key role in early prostate epithelia cell transformation and PCa growth. The purpose of this study is to investigate the effect of metformin on c-myc expression and PCa progression. Our results demonstrated that (i) in Hi-Myc mice that display murine prostate neoplasia and highly resemble the progression of human prostate tumors, metformin attenuated the development of prostate intraepithelial neoplasia (PIN, the precancerous lesion of prostate) and PCa lesions. (ii) Metformin reduced c-myc protein levels in vivo and in vitro. In Myc-CaP mouse PCa cells, metformin decreased c-myc protein levels by at least 50%. (iii) Metformin selectively inhibited the growth of PCa cells by stimulating cell cycle arrest and apoptosis without affecting the growth of normal prostatic epithelial cells (RWPE-1). (iv) Reduced PIN formation by metformin was associated with reduced levels of androgen receptor and proliferation marker Ki-67 in Hi-Myc mouse prostate glands. Our novel findings suggest that by downregulating c-myc, metformin can act as a chemopreventive agent to restrict prostatic neoplasia initiation and transformation.

UR - http://www.scopus.com/inward/record.url?scp=84889001940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889001940&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgt307

DO - 10.1093/carcin/bgt307

M3 - Article

C2 - 24130167

AN - SCOPUS:84889001940

VL - 34

SP - 2823

EP - 2832

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 12

ER -